Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling ...

Eli Lilly (LLY) launched its blockbuster ... Reuters’ Rishika Sadam reports. Mounjaro, a once-weekly injection approved by India’s drug regulator, is priced at 4,375 rupees or $50.67 for ...

Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro – which targets GLP-1 but also activates ...

HYDERABAD/BENGALURU (Reuters) -Eli ... based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the ...

HYDERABAD (Reuters) -Eli Lilly launched its blockbuster ... interest also boosting the drugmakers' valuations. Mounjaro, a once-weekly injection approved by India's drug regulator, is priced ...